FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2209448786> ?p ?o ?g. }

• W2209448786 endingPage "173" @default.
• W2209448786 startingPage "164" @default.
• W2209448786 abstract "Pretreatment with anti-thymocyte globulin (ATG) decreases the occurrence of chronic graft-versus-host disease (CGVHD) after haemopoietic cell transplantation from an unrelated donor, but evidence of patient benefit is absent. We did a study to test whether ATG provides patient benefit, particularly in reducing the need for long-term immunosuppressive treatment after transplantation.We did a phase 3, multicentre, open-label, randomised controlled trial at ten transplant centres in Canada and one in Australia. Eligible patients were aged 16 to 70 years with any haematological malignancy and a Karnofsky score of at least 60 receiving either myeloablative or non-myeloablative (or reduced intensity) conditioning preparative regimens before haemopoietic cell transplantation from an unrelated donor. We allocated patients first by simple randomisation (1:1), then by a minimisation method, to either pretransplantation rabbit ATG plus standard GVHD prophylaxis (ATG group) or standard GVHD prophylaxis alone (no ATG group). We gave a total dose of ATG of 4·5 mg/kg intravenously over 3 days (0·5 mg/kg 2 days before transplantation, 2·0 mg/kg 1 day before, and 2·0 mg/kg 1 day after). The primary endpoint was freedom from all systemic immunosuppressive drugs without resumption up to 12 months after transplantation. Analysis was based on a modified intention-to-treat method. This trial was registered at ISRCTN, number 29899028.Between June 9, 2010, and July 8, 2013, we recruited and assigned 203 eligible patients to treatment (101 to ATG and 102 to no ATG). 37 (37%) of 99 patients who received ATG were free from immunosuppressive treatment at 12 months compared with 16 (16%) of 97 who received no ATG (adjusted odds ratio 4·25 [95% CI 1·87-9·67]; p=0·00060. The occurrence of serious adverse events (Common Terminology Criteria grades 4 or 5) did not differ between the treatment groups (34 [34%] of 99 patients in the ATG group vs 41 [42%] of 97 in the no ATG group). Epstein-Barr virus reactivation was substantially more common in patients who received ATG (20 [one of whom died-the only death due to an adverse event]) versus those who did not receive ATG (two [no deaths]). No deaths were attributable to ATG.ATG should be added to myeloblative and non-myeloblative preparative regimens for haemopoietic cell transplantation when using unrelated donors. The benefits of decreases in steroid use are clinically significant. Epstein-Barr virus reactivation is increased, but is manageable by prospective monitoring and the use of rituximab. Future trials could determine whether the doses of ATG used in this trial are optimum, and could also provide additional evidence of a low relapse rate after non-myeloablative regimens.The Canadian Institutes of Health Research and Sanofi." @default.
• W2209448786 created "2016-06-24" @default.
• W2209448786 creator A5001538581 @default.
• W2209448786 creator A5002129758 @default.
• W2209448786 creator A5008056180 @default.
• W2209448786 creator A5021987793 @default.
• W2209448786 creator A5026879640 @default.
• W2209448786 creator A5031390636 @default.
• W2209448786 creator A5031948436 @default.
• W2209448786 creator A5034812867 @default.
• W2209448786 creator A5040551037 @default.
• W2209448786 creator A5045042696 @default.
• W2209448786 creator A5051289075 @default.
• W2209448786 creator A5051290569 @default.
• W2209448786 creator A5055324220 @default.
• W2209448786 creator A5073327231 @default.
• W2209448786 creator A5076501249 @default.
• W2209448786 creator A5083858828 @default.
• W2209448786 creator A5091222951 @default.
• W2209448786 creator A5091286100 @default.
• W2209448786 date "2016-02-01" @default.
• W2209448786 modified "2023-10-16" @default.
• W2209448786 title "Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial" @default.
• W2209448786 cites W1530411906 @default.
• W2209448786 cites W1975020079 @default.
• W2209448786 cites W1980288572 @default.
• W2209448786 cites W1980914191 @default.
• W2209448786 cites W1982245010 @default.
• W2209448786 cites W1996893745 @default.
• W2209448786 cites W1998006433 @default.
• W2209448786 cites W2008706768 @default.
• W2209448786 cites W2011792098 @default.
• W2209448786 cites W2025459079 @default.
• W2209448786 cites W2028590977 @default.
• W2209448786 cites W2034898311 @default.
• W2209448786 cites W2037668591 @default.
• W2209448786 cites W2038981426 @default.
• W2209448786 cites W2048449366 @default.
• W2209448786 cites W2062576298 @default.
• W2209448786 cites W2065984640 @default.
• W2209448786 cites W2069377065 @default.
• W2209448786 cites W2069726212 @default.
• W2209448786 cites W2073140442 @default.
• W2209448786 cites W2106781384 @default.
• W2209448786 cites W2108361431 @default.
• W2209448786 cites W2112778345 @default.
• W2209448786 cites W2127721329 @default.
• W2209448786 cites W2149843919 @default.
• W2209448786 cites W2152197116 @default.
• W2209448786 cites W2164885965 @default.
• W2209448786 cites W2167765664 @default.
• W2209448786 cites W2618073389 @default.
• W2209448786 cites W4237219709 @default.
• W2209448786 doi "https://doi.org/10.1016/s1470-2045(15)00462-3" @default.
• W2209448786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26723083" @default.
• W2209448786 hasPublicationYear "2016" @default.
• W2209448786 type Work @default.
• W2209448786 sameAs 2209448786 @default.
• W2209448786 citedByCount "255" @default.
• W2209448786 countsByYear W22094487862016 @default.
• W2209448786 countsByYear W22094487862017 @default.
• W2209448786 countsByYear W22094487862018 @default.
• W2209448786 countsByYear W22094487862019 @default.
• W2209448786 countsByYear W22094487862020 @default.
• W2209448786 countsByYear W22094487862021 @default.
• W2209448786 countsByYear W22094487862022 @default.
• W2209448786 countsByYear W22094487862023 @default.
• W2209448786 crossrefType "journal-article" @default.
• W2209448786 hasAuthorship W2209448786A5001538581 @default.
• W2209448786 hasAuthorship W2209448786A5002129758 @default.
• W2209448786 hasAuthorship W2209448786A5008056180 @default.
• W2209448786 hasAuthorship W2209448786A5021987793 @default.
• W2209448786 hasAuthorship W2209448786A5026879640 @default.
• W2209448786 hasAuthorship W2209448786A5031390636 @default.
• W2209448786 hasAuthorship W2209448786A5031948436 @default.
• W2209448786 hasAuthorship W2209448786A5034812867 @default.
• W2209448786 hasAuthorship W2209448786A5040551037 @default.
• W2209448786 hasAuthorship W2209448786A5045042696 @default.
• W2209448786 hasAuthorship W2209448786A5051289075 @default.
• W2209448786 hasAuthorship W2209448786A5051290569 @default.
• W2209448786 hasAuthorship W2209448786A5055324220 @default.
• W2209448786 hasAuthorship W2209448786A5073327231 @default.
• W2209448786 hasAuthorship W2209448786A5076501249 @default.
• W2209448786 hasAuthorship W2209448786A5083858828 @default.
• W2209448786 hasAuthorship W2209448786A5091222951 @default.
• W2209448786 hasAuthorship W2209448786A5091286100 @default.
• W2209448786 hasConcept C126322002 @default.
• W2209448786 hasConcept C141071460 @default.
• W2209448786 hasConcept C168563851 @default.
• W2209448786 hasConcept C203092338 @default.
• W2209448786 hasConcept C2779972918 @default.
• W2209448786 hasConcept C2780252810 @default.
• W2209448786 hasConcept C2780882860 @default.
• W2209448786 hasConcept C2911091166 @default.
• W2209448786 hasConcept C71924100 @default.
• W2209448786 hasConcept C81358767 @default.
• W2209448786 hasConcept C90924648 @default.
• W2209448786 hasConceptScore W2209448786C126322002 @default.

• next